Latest Content

Experts discuss rapid cycling and bipolar II, and weigh lithium as an often overlooked treatment option.

How antidepressant myths can raise suicide risk—and what evidence-based prescribing, tapering, and crisis supports really look like.

Anti-inflammatory drugs ease anhedonia and depressive symptoms in high-CRP depression, spotlighting CRP-guided treatment and lifestyle strategies while calling for stronger RCTs.

Anosognosia drives untreated schizophrenia into homelessness and jail. Here's why civil care fails and how structured treatment can decrease the number of arrests.

Large meta-analysis finds GLP-1 drugs don’t raise depression or suicidality and modestly boost quality of life and eating control in diabetes/obesity.

Review news from the last week in psychiatry.

Leading psychiatric organizations respond to federal push for deprescribing.

Renaming borderline personality disorder fails to address the condition's complexity; keeping the term preserves key clinical meaning, including structural traits and stress-related psychotic symptoms.

Psilocybin therapy shows fast, lasting relief for depression; clinicians discuss trial hurdles and emerging promise for PTSD and addiction in this podcast.

Get real-time psychiatry conference highlights with video interviews, session takeaways, and quick clips from APA and psychopharmacology meetings.

Online tool personalizes antidepressant choice in primary care, cutting dropouts and improving 24-week depression and anxiety scores.

New psychiatry drugs target dementia agitation, ADHD, depression, TRD, and schizophrenia—see which novel mechanisms may reach the FDA next.

FDA clears MIND1 trial testing NRX-101 plus robotic TMS to curb suicidality in treatment-resistant depression, with military-focused sites.